Table 3 Artesunate–amodiaquine and artemether-lumefantrine efficacy on day 28 in Owando, Republic of Congo
From: Malaria burden and anti-malarial drug efficacy in Owando, northern Congo
| ASAQ | AL | |
|---|---|---|
| No. of included patients (intention-to-treat) | 62 | 61 |
| PCR-uncorrected responses on day 28 | ||
| Withdrawn or lost to follow up: N; % (95 % CI) | 7; 11.3 (4.7–21.9) | 9; 14.8 (7.0–26.2) |
| Per protocol population: N; % (95 % CI) | 55; 88.7 (78.1–95.3) | 52; 85.2 (73.8–93.0) |
| Failures: N; % (95 % CI) | 4; 7.3 (2.0–17.6) | 4; 7.7 (2.1–18.5) |
| ETF: N; % (95 % CI) | 0; 0 (0–5.8) | 1; 1.9 (0–10.3) |
| LCF: N; % (95 % CI) | 1; 1.8 (0–9.7) | 1; 1.9 (0–10.3) |
| LPF : N; % (95 % CI) | 3; 5.5 (1.1–15.1) | 2; 3.8 (0.5–13.2) |
| ACPR: N; % (95 % CI) | 51; 92.7 (82.4–98.0) | 48; 92.3 (81.5–97.9) |
| PCR-corrected responses on day 28 | ||
| Withdrawn + lost-to-follow-up + censured due to new infections: N; % (95 % CI) | 11; 17.7 (9.2–29.5) | 12; 19.7 (10.6–31.8) |
| Per protocol population: N; % (95 % CI) | 51; 82.3 (70.5–90.8) | 49; 80.3 (68.2–89.4) |
| ETF: N; % (95 % CI) | 0; 0 (0–7.0) | 1; 2.0 (0.1–10.9) |
| Recrudescence: N; % (95 % CI) | 0; 0 (0–7.0) | 0; 0 (0–7.2) |
| ACPR: N; % (95 % CI) | 51; 100 (93.0–100) | 48; 98.0 (89.1–99.9) |
| New infections: n/N (%) | 4/4 (100) | 3/3 (100) |